European Pharmaceutical Review

OCTOBER 17, 2024

World Allergy Organization (WAO) White Book on Allergy 2011-2012: Executive Summary. Finger Injection With High-Dose (1:1,000) Epinephrine: Does It Cause Finger Necrosis And Should It Be Treated? Hand (N Y). 2007; 2(1):5-11. Derived from IQVIA Claims Data, 2023. Casale TB, Ellis AK, Nowak-Wegrzyn A, et al.

Food and Drug Administration 121

Food and Drug Administration Medicine Consulting Food 121

Copyright Clearance Center

MAY 22, 2024

Serials has been fully digitised and is openly accessible at serials.uksg.org.

40

40

European Pharmaceutical Review

MARCH 1, 2024

MHRA confirmed that this new marketing authorisation was granted to Amgen Limited, as a line extension of the original marketing authorisation for XGEVA 120mg solution for injection, which was granted on 13 July 2011. The post New antibody drug formulation wins novel MHRA approval appeared first on European Pharmaceutical Review.

Medicine 97

Medicine Healthcare Healthcare Marketing 97

Pharmaceutical Technology

JUNE 19, 2023

Novartis and Incyte Corp’s Jakafi was the first FDA-approved drug for the treatment of myelofibrosis in November 2011. First-in-line treatment for myelofibrosis currently involves treatment with Jakafi (ruxolitinib) in combination with other drugs such as danazol.

Food and Drug Administration 98

Food and Drug Administration FDA Prescription Food 98

World of DTC Marketing

MAY 2, 2021

On a percentage basis, the figure for 2020 was Independence’s highest profit margin since 2011, records show. IBC, the Philadelphia region’s largest health insurer , on Tuesday reported 2020 net income of $622 million — almost double its $321 million income in 2019, before COVID-19 struck. The company also did well in the stock market.

Healthcare 277

Healthcare Healthcare Insurance Government 277

European Pharmaceutical Review

DECEMBER 14, 2023

Between 1999 and 2001, it supported 17 percent of withdrawals, between 2002 and 2011, it supported 26 percent of withdrawals and by 2012 to 2016, 80 percent of withdrawals were supported by observational studies (cohort, case-control, or other epidemiologic design). Meta-analyses contributed least frequently (31.4 EMA/95098/2010.

Medicine 116

Medicine Safety Competition Networking 116

World of DTC Marketing

NOVEMBER 5, 2021

.” 95% of diets fail and most will regain their lost weight in 1-5 years (Source: Statistics on Weight Discrimination: A Waste of Talent , The Council on Size and Weight Discrimination, Retrieved July 18, 2011, from ([link] The “obesity industry” (commercial weight-loss programs, weight-loss drug manufacturers, and bariatric surgery centers ) (..)

Insurance 271

Insurance Side effects Medical Prescription 271

pharmaphorum

JANUARY 25, 2023

BMS’ lawsuit claims that Imjudo (tremelimumab) infringes two patents covering its own CTLA4 drug Yervoy (ipilimumab), which has been on the market since 2011 and is a key component of combination therapies for cancer with BMS’ PD-1 inhibitor Opdivo (nivolumab).

FDA 52

FDA Marketing Sales Pharma 52

European Pharmaceutical Review

AUGUST 23, 2022

To achieve this objective, the regulation amends Directive 2011/24/EU on the application of patients’ rights in cross?border Directive 2011/24/EU had the merit of drawing attention to the need for an appropriate and centralised assessment of health technologies but failed to ensure effective harmonisation on the issue. Lorgelly PK.,

Consulting 98

Consulting Medical Healthcare Healthcare 98

Pharmaceutical Technology

APRIL 7, 2023

Makena was approved by the FDA under the accelerated approval pathway in 2011 to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of spontaneous preterm birth. The decision was made after studies did not prove the effectiveness of the drug in preventing preterm birth.

Food and Drug Administration 97

Food and Drug Administration FDA Food Pharma 97

Pharmaceutical Technology

APRIL 7, 2023

Makena was approved by the FDA under the accelerated approval pathway in 2011 to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of spontaneous preterm birth. The decision was made after studies did not prove the effectiveness of the drug in preventing preterm birth.

Food and Drug Administration 95

Food and Drug Administration FDA Food Pharma 95

World of DTC Marketing

AUGUST 27, 2021

The FDA approved 309 new drugs between 2011 and 2018, 38 per year on average. More than 40 million patients are needed to meet the demand of currently enrolling trials. According to antidote.com. More than 18,000 clinical trials are actively recruiting patients in the U.S. In 2018, the FDA approved 59 new drugs – an all-time high.

Recruitment 187

Recruitment Patients FDA Medical 187

Medical Device Success

DECEMBER 18, 2011

I sincerely hope all of you have had a productive and successful 2011. If you have struggled in 2011, let me know, perhaps I can share some ideas for success. The difference between Strategies and Tactics www.medicaldevicesuccess.com/2011/01/04/critical-the-difference-between-strategies-and-tactics/.

Medical 100

Medical Sales Marketing Consulting 100

Copyright Clearance Center

OCTOBER 1, 2022

When Marybeth left the Copyright Office, we were privileged to welcome her to CCC’s Board where she was a Director for seven years from 2011-2017. She was a global thought and policy leader and a beloved mentor to many generations of copyright professionals and lawyers.

59

59

Pharmaceutical Technology

NOVEMBER 3, 2022

A Quantitative View on Award Criteria in Tenders in the EU5 from 2011 to 2020 , Genane C, Trenti S In-Person and Virtual Poster Session 3 Date: Tuesday 8 November 2022 Poster Session Time: 10:00–13:15 HPR150: P&R Policies and Macro-Trends Pertinent to CGTs: Where Are the Main Barriers and Who Leads the Efforts to a Greater Access?

Pharma 52

Pharma Leads Medical Pharmaceutical 52

Pharmaceutical Technology

APRIL 20, 2023

Initially reported in 2011, CircRNA is a naturally occurring class of RNA. Targovax has unveiled plans to rebrand as Circio , reflecting its strategic shift to focus on expediting the development of its innovative circular RNA (circRNA) platform.

Engineering 96

Engineering Leads Medicine Pharmaceutical 96

Legacy MEDSearch

MAY 3, 2023

Leadership includes Joy Celebre (recruiting since 1996, joined in 2008), Carolyn Jones (recruiting since 1995, joined in 2011), Arshad Alam (recruiting since 1995, joined 2017), John White (Talent Sourcing Manager, joined 2012), and Partner Chris Miclot, (joined 2012). “In

Recruitment 98

Recruitment Medical Management Media 98

World of DTC Marketing

AUGUST 19, 2022

Data from the Kaiser Family Foundation (KFF) shows that between 2011 and 2021, the average premiums for family coverage rose from $15,073 to $22,221—an increase of 47.4%. As the U.S. population health issues increase, the risk of insuring the average American goes up.

Healthcare 204

Healthcare Healthcare Insurance Competition 204

pharmaphorum

JULY 6, 2022

A European Federation of Pharmaceutical Industries and Associations (EFPIA) report published earlier this year, for example, compared the timelines of six regulatory agencies between 2011 and 2020. It found the EMA “lagged behind” most, with a median approval time in 2020 of more than 400 days.

Safety 95

Safety FDA Medicine Patients 95

European Pharmaceutical Review

SEPTEMBER 13, 2023

The new rules will repeal the 2011 Directive on late payments and will replace it with a Regulation. According to the EC, the recent SME performance report established that SME value added for 2023 is still forecast to stay at 3.6 This is compared to 1.8 percent for large enterprises, which is lower than its 2019 level.

Pharma 96

Pharma Competition Marketing Training 96

Impetus Digital

SEPTEMBER 21, 2022

He started his career in banking and business line management before going through the MBA program at Berkeley in 2011. Marius Rus Founder Marius Rus is a finance and strategy expert turned healthcare entrepreneur.

Consulting 52

Consulting Professional Services Healthcare Provider Healthcare 52

European Pharmaceutical Review

MARCH 7, 2024

He then worked at BCG from 2004 to 2011, where he developed expertise in the energy, engineering, and high-tech sectors. Julien joined Areva in 2011, initially working in the group’s strategy department before taking up the position of Chairman and General Manager of Areva Nuclear Power in China.

Manufacturing 52

Manufacturing Food and Drug Administration Marketing Management 52

PM360

JUNE 29, 2022

The line from the 2011 Pixar “Cars” sequel (trust me, as a parent of two, I have seen it countless times) points to the practical implication for voice technology. “Everything is voice activated these days.”

Marketing 96

Marketing Patients Healthcare Provider Prescription 96

pharmaphorum

DECEMBER 29, 2022

The case revolves around allegations that Novartis made an agreement in 2011 with Par Pharmaceutical when Exforge (valsartan/amlodipine) was nearing the end of its patent life that was designed to keep Par’s generic version of the drug off the market until 30 September, 2014.

Retail 52

Retail Marketing Doctors Government 52

pharmaphorum

AUGUST 8, 2022

In 2011 it paid $340 million for rights to rivipansel , a pan-selectin antagonist developed by GlycoMimetics, which failed a phase 3 test in 2019 and was jettisoned by Pfizer the following year. It’s worth noting that this isn’t Pfizer’s first deal in SCD.

Marketing 106

Marketing Sales Pharma FDA 106

Clarivate

OCTOBER 4, 2023

In 2011, following a review of available IP management software (IPMS), Philips adopted Unycom. The Solution: Unified IP lifecycle management In 2008, Philips turned to ipan, now part of Clarivate , to handle renewals. Since then, the relationship has expanded to include European Patent (EP) validations and IP recordals.

Management 59

Management Networking Leads Patients 59

Pharmaceutical Technology

APRIL 27, 2023

Established in 2011, the CDF is a source of funding to increase patient access to cancer drugs in the UK. The UK’s National Institute for Health and Care Excellence (NICE) has recommended two new personalised immunotherapy therapies from Kite Pharma to treat aggressive forms of blood cancer for the Cancer Drugs Fund (CDF).

Patients 59

Patients Medicine Pharma Leads 59

European Pharmaceutical Review

APRIL 8, 2024

Yet from 2011, these arrangements were the subject of “patent-non- exclusive rights, technology- exclusive rights and technology-supply”. Until 2010, contract manufacturing arrangements were for contract manufacturing (drug-manufacturing/supply) of antibody drugs.

Manufacturing 52

Manufacturing Networking Pharmaceutical Marketing 52

pharmaphorum

OCTOBER 9, 2022

Chowiria was previously chairman and CBO at Nektar 2011 when it was trying to build a business in respiratory therapeutics including a now-defunct inhaled formulation of insulin. One link between the two companies lies in PureTech’s president and chief business officer Bharat Chowiria, note analysts at Mizuho.

Leads 59

Leads Healthcare Healthcare 59

PM360

OCTOBER 25, 2022

The digital health sector has grown significantly during the past decade, with $2 billion invested in 2011 and $44 billion in 2021 by the global financial and corporate markets. In the shadow of the pandemic, tremendous investment poured into digital health. But in the past year, investors have been more selective in their decisions.

Marketing 98

Marketing Leads Healthcare Healthcare 98

Pharmaceutical Technology

NOVEMBER 14, 2022

In August 2021, Saphnelo, a type 1 interferon receptor antibody, became the first lupus treatment to be approved since GSK’s Benlyta (belimumab) won a regulatory nod in 2011. MSCs and CAR-Ts for lupus. As per AstraZeneca's recent Q3 earnings, Saphnelo has yielded $69 million to date this year.

Side effects 144

Side effects Patients Manufacturing Safety 144

World of DTC Marketing

FEBRUARY 4, 2021

regulators knew about reports of suicidal behavior in men taking the anti-baldness treatment Propecia when they decided not to warn consumers of those potential risks in a 2011 update of the popular drug’s label. Newly unsealed court documents show that Merck and U.S. Annual U.S.

Pharma 180

Pharma Food and Drug Administration Side effects Safety 180

Medical Device Success

NOVEMBER 17, 2010

Then I ask you, “Do you have a formal written plan that articulates the strategies and tactics you will follow in 2011?” Write down the fact you will make a strategic plan for 2011 or the next 6 months…whatever. If you are driving a car, you know that it will take less time to follow the path of A to E and it will cost less in fuel.

Sales 100

Sales Medical Marketing Consulting 100

European Pharmaceutical Review

SEPTEMBER 22, 2022

11 have recently conducted an analysis of international HTA submissions from 2011-2019 to determine the acceptability of single arm clinical studies and ECs as part of the drug reimbursement process. 2011 May; 46(3): 399–424. Patel et al. FDA presentation. Available at: [link]. Multivariate Behav Res. doi: 1080/00273171.2011.568786.

Food and Drug Administration 122

Food and Drug Administration Patients Distribution FDA 122

European Pharmaceutical Review

JULY 4, 2024

Herbal medicines placed on the market since April 2011 must have either a traditional herbal registration (THR) or a Marketing Authorisation (MA). 6 Thus, it is critical to ensure the consistency of therapeutic effect across batches (see box). 10,12 The THR scheme is also limited to products used for oral or external use and/or inhalation.

Marketing 103

Marketing Food and Drug Administration Medicine Prescription 103

PM360

OCTOBER 24, 2022

Through the GoodRx App, savings cards, and their website, GoodRx has saved Americans over $35 billion on prescriptions and avoid $60 million in hospitalization costs since 2011. Innovation.

Insurance 40

Insurance Prescription Healthcare Healthcare 40

PM360

SEPTEMBER 17, 2024

About FINN Partners, Inc.    Founded in 2011 on the core principles of innovation and collaborative partnership, FINN Partners has grown from about $24 million in fees to almost $200 million in fees during the past 12 years, becoming one of the fastest-growing independent public relations agencies in the world.

Leads 52

Leads Management Marketing Biopharma 52